Clinical Trial Update: Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of KD019 and trastuzumab in HER2-positive metastatic breast cancer, terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Malignant Neoplasm to Brain

Drugs mentioned

• KD019
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-03-24